RYAN
2.12.2021 08:02:10 CET | Business Wire | Press release
Ryan , a leading global tax services and software provider, today announced the acquisition of Qvalia’s value added tax (VAT) compliance and recovery business. As a major market provider of VAT services in the Nordics, this acquisition significantly expands Ryan’s brand in the region and continues to strengthen and grow its service offerings across Europe.
“Ryan’s commitment to our clients in the European region is evident by our expansion into the Nordics,” said Ryan Chairman and CEO G. Brint Ryan . “We’re thrilled to welcome Qvalia’s highly experienced tax professionals to our workplace. Our clients will benefit from Qvalia’s leading VAT recovery and compliance services in the Nordics, while Qvalia’s clients can now take advantage of Ryan’s full suite of tax services globally, creating tax centres of excellence.”
Founded in 2007, with headquarters in Stockholm, Sweden and offices in Norway, Finland, and Denmark, Qvalia has helped the region’s largest organisations analyse accounting data, manage costs, reduce risks, and improve the entire tax process. This strategic acquisition adds 32 highly qualified VAT professionals, located across four new office locations to Ryan’s European team, including Qvalia’s four senior country leaders: Michael Bernhardtsen in Denmark, Andre Klemsdal in Norway, Teemu Kamu in Finland, and Cathrine Engman in Sweden. Collectively, with more than 40 years of experience, they will focus on Ryan’s growth trajectory in their respective country markets, bringing additional value to their existing clients.
“The addition of Qvalia’s VAT compliance and recovery team further solidifies Ryan as a leading provider of VAT services in Europe. Qvalia’s innovative and transformative approach and culture are a powerful fit with our mission to help our clients transform their tax function into centers of excellence,” said Jon C. Sweet, Ryan’s President of European and Asia-Pacific Operations . “This acquisition not only positions Ryan as the preeminent VAT provider in the Nordics, but it also strengthens our VAT compliance and recovery practice throughout Europe.”
Qvalia’s finance process automation platform and fintech will continue to operate under the Qvalia name and brand and will not be included as part of the acquisition. With significant synergies existing between the two companies, there will be continued opportunities for both Qvalia’s and Ryan’s combined client base to leverage discreet offerings, as the two organisations partner prospectively.
“This is an exciting opportunity for Qvalia’s VAT compliance and recovery team to join a global leading tax firm. After founding and growing this practice over the last 15 years, I am confident this team will bring valuable in-depth knowledge, expertise, and experience of the Nordic market to Ryan,” said Henri Taipale, CEO and founder of Qvalia, who will be focusing on further growing Qvalia’s finance process automation platform. “I am looking forward to continuing to partner with Ryan and joining forces to be able to serve our mutual clients in an excellent and innovative way.”
About Ryan
Ryan, an award-winning global tax services and software provider, is the largest Firm in the world dedicated exclusively to business taxes. The Firm provides an integrated suite of international tax services on a multijurisdictional basis, including cost management, compliance, consulting, and technology services. Ryan is a nine-time recipient of the International Service Excellence Award from the Customer Service Institute of America (CSIA) for its commitment to world-class client service. Empowered by the dynamic myRyan work environment, which is widely recognised as the most innovative in the tax services industry, Ryan’s multidisciplinary team of more than 3,100 professionals and associates serves over 18,000 clients in more than 60 countries, including many of the world’s most prominent Global 5000 companies. More information about Ryan can be found at ryan.com/europe. “Ryan” and “Firm” refer to the global organisational network and may refer to one or more of the member firms of Ryan International, each of which is a separate legal entity.
About Qvalia
Qvalia redesigns finance processes. Founded in 2007, the company expanded to become the leading Nordic expert in financial data mining. Since 2017, the company has developed a platform for finance teams to automate financial processes, including e-invoicing, accounting, and analytics. The company has offices in Stockholm, Helsinki, Copenhagen, and Oslo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201006097/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
